GlaxoSmithKline, Medicines Research Centre, Via A. Fleming, 4, 37100 Verona, Italy.
Bioorg Med Chem. 2011 Jul 15;19(14):4257-73. doi: 10.1016/j.bmc.2011.05.057. Epub 2011 Jun 6.
This article deals with the synthesis and the activities of some 1,5-dialkyl-3-arylureido-1,5-benzodiazepin-2,4-diones which were prepared as potential CCK2 antagonists, with the intention to find a possible follow up of our lead compound GV150013, showing an improved pharmacokinetic profile. The phenyl ring at N-5 was replaced with more hydrophilic substituents, like alkyl groups bearing basic functions. In some cases, the resolution of the racemic key intermediates 3-amino-benzodiazepines was also accomplished. Among the compounds synthesized and characterised so far in this class, the 5-morpholinoethyl derivative 54, was selected as potential follow up of GV150013 and submitted for further evaluation.
本文涉及一些 1,5-二烷基-3-芳基脲基-1,5-苯并二氮杂卓-2,4-二酮的合成和活性,这些化合物被制备为潜在的 CCK2 拮抗剂,旨在寻找我们的先导化合物 GV150013 的可能后续研究,该化合物显示出改善的药代动力学特性。N-5 位的苯环被更亲水的取代基取代,如带有碱性官能团的烷基。在某些情况下,还完成了手性关键中间体 3-氨基苯并二氮杂卓的拆分。在迄今合成和表征的这类化合物中,5-吗啉乙基衍生物 54 被选为 GV150013 的潜在后续研究,并提交进一步评估。